Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Everolimus in Metastatic CRPC
NCT01051570Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Feb 2010
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Time to Progression. Started Feb 2010; status: completed.
02
Drugs
everolimus
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01051570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051570.